Conclusion Although the totality of scientific evidence supports sacubitril/valsartan as having
incremental efficacy over valsartan in a broad population of patients with HF and EF> 40 …

Objectives: The aim of this study was to assess the prevalence and variation in angiotensin
receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart …

Background: While disease-modifying therapies exist for heart failure (HF) with reduced left
ventricular ejection fraction (LVEF), few options are available for patients in the higher range …

Aims We systematically reviewed the European real‐world evidence (RWE) about sacubitril‐
valsartan for heart failure with reduced ejection fraction. Methods and results Twenty‐one …

Aims The study aims to explore the real‐world titration patterns of sacubitril/valsartan in a
chronic heart failure (HF) follow‐up management system and the effect on the recovery of …

Background: Sacubitril/valsartan improves heart failure (HF) outcomes in patients with heart
failure with reduced ejection fraction (HFrEF). However, randomized controlled trials (RCTs) …

Purpose PARADIGM-HF demonstrated the superiority of sacubitril/valsartan over enalapril in
patients with heart failure and reduced ejection fraction (HF-REF). How widely applicable …

Objectives To determine efficacy and safety of sacubitril/valsartan compared with enalapril in
Indian patients of PARADIGM-HF trial. Methods A randomized, double-blind, active …

Background Limited evidence is available regarding low (24/26 mg) and middle (49/51 mg)
doses of sacubitril/valsartan. Objectives The purpose of this study was to investigate the …

Aims The efficacy and safety of sacubitril/valsartan for patients with heart failure with
preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the …